US Patent

US9474780 — GIP and GLP-1 co-agonist compounds

Composition of Matter · Assigned to Eli Lilly and Co · Expires 2036-01-05 · 10y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

Eli Lilly and Co's patent US 9474780 protects dual incretin peptide mimetic compounds that agonize both GIP and GLP-1 receptors.

USPTO Abstract

The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro
U-4374 — Mounjaro

Patent Metadata

Patent number
US9474780
Jurisdiction
US
Classification
Composition of Matter
Expires
2036-01-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.